744218-85-7 Usage
Description
SAM-315 is a novel small molecule inhibitor of p300/CBP-associated factor (PCAF) and histone acetyltransferase (HAT) activity. It functions as a potent and selective inhibitor of PCAF, thereby inhibiting the acetylation of histone and non-histone proteins. It has shown promise as a potential therapeutic agent for the treatment of a variety of human diseases, including cancer, neurodegenerative diseases, and inflammatory disorders.
Used in Pharmaceutical Industry:
SAM-315 is used as a therapeutic agent for the treatment of various human diseases, including cancer, neurodegenerative diseases, and inflammatory disorders. It inhibits tumor growth and metastasis in cancer models, reduces inflammation in inflammatory disease models, and improves cognitive function in neurodegenerative disease models. Its ability to target histone acetylation and PCAF activity makes it a promising candidate for further development as a therapeutic agent.
Check Digit Verification of cas no
The CAS Registry Mumber 744218-85-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,4,4,2,1 and 8 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 744218-85:
(8*7)+(7*4)+(6*4)+(5*2)+(4*1)+(3*8)+(2*8)+(1*5)=167
167 % 10 = 7
So 744218-85-7 is a valid CAS Registry Number.
744218-85-7Relevant articles and documents
5-piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists
Liu, Kevin G.,Robichaud, Albert J.,Bernotas, Ronald C.,Yan, Yinfa,Lo, Jennifer R.,Zhang, Mei-Yi,Hughes, Zoe A.,Huselton, Christine,Zhang, Guo Ming,Zhang, Jean Y.,Kowal, Dianne M.,Smith, Deborah L.,Schechter, Lee E.,Comery, Thomas A.
experimental part, p. 7639 - 7646 (2011/02/21)
As part of our efforts to develop agents for CNS diseases, we have been focused on the 5-HT6 receptor in order to identify potent and selective ligands for cognitive enhancement. Herein we report the identification of a novel series of 5-piperazinyl-3-sulfonylindazoles as potent and selective 5-HT6 antagonists. The synthesis, SAR, and pharmacokinetic and pharmacological activities of some of the compounds including 3-(naphthalen-1-ylsulfonyl)-5-(piperazin-1-yl)-1H-indazole (WAY-255315 or SAM-315) will be described.
